Liquidia (NASDAQ:LQDA) Trading Up 3.3% After Analyst Upgrade

Liquidia Co. (NASDAQ:LQDA) shares were up 3.3% during trading on Thursday after Scotiabank raised their price target on the stock from $30.00 to $34.00. Scotiabank currently has a sector outperform rating on the stock. Liquidia traded as high as $15.45 and last traded at $15.42. Approximately 549,711 shares traded hands during trading, a decline of 41% from the average daily volume of 928,447 shares. The stock had previously closed at $14.92.

A number of other research analysts have also recently commented on the stock. Needham & Company LLC raised their price target on shares of Liquidia from $19.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday. Wells Fargo & Company started coverage on shares of Liquidia in a research note on Friday, December 20th. They issued an “overweight” rating and a $20.00 target price for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $29.00 target price on shares of Liquidia in a research note on Thursday. One analyst has rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $26.63.

Insider Activity

In related news, insider Rajeev Saggar sold 2,445 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $13.00, for a total value of $31,785.00. Following the completion of the transaction, the insider now owns 267,943 shares in the company, valued at $3,483,259. The trade was a 0.90 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, General Counsel Russell Schundler sold 16,393 shares of the business’s stock in a transaction that occurred on Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total transaction of $193,109.54. Following the completion of the transaction, the general counsel now owns 573,478 shares of the company’s stock, valued at $6,755,570.84. This trade represents a 2.78 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 71,245 shares of company stock worth $843,326. Insiders own 30.10% of the company’s stock.

Institutional Trading of Liquidia

A number of institutional investors have recently bought and sold shares of LQDA. Steward Partners Investment Advisory LLC acquired a new stake in Liquidia during the 4th quarter worth $59,000. Summit Investment Advisors Inc. grew its holdings in Liquidia by 35.0% during the 4th quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company’s stock worth $78,000 after acquiring an additional 1,719 shares during the period. Walleye Trading LLC grew its holdings in Liquidia by 54.7% during the 3rd quarter. Walleye Trading LLC now owns 13,201 shares of the company’s stock worth $132,000 after acquiring an additional 4,670 shares during the period. D. E. Shaw & Co. Inc. acquired a new stake in Liquidia during the 4th quarter worth $142,000. Finally, EntryPoint Capital LLC acquired a new stake in Liquidia during the 4th quarter worth $154,000. Institutional investors and hedge funds own 64.54% of the company’s stock.

Liquidia Trading Down 2.1 %

The business’s fifty day simple moving average is $14.79 and its 200 day simple moving average is $12.18. The stock has a market cap of $1.28 billion, a price-to-earnings ratio of -9.28 and a beta of 0.07.

Liquidia (NASDAQ:LQDA) last released its earnings results on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.08). Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. The business had revenue of $2.92 million for the quarter, compared to analyst estimates of $4.60 million. As a group, research analysts anticipate that Liquidia Co. will post -1.51 earnings per share for the current year.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).